Medicus Pharma Announces $135M M&A Deal
Medicus Pharma announced that its wholly-owned subsidiary, SkinJect, Inc., has entered into a non-binding letter of intent for a business combination with an undisclosed SPAC. The proposed transaction contemplates a $135 million pre-money enterprise valuation for SkinJect and is expected to close in the first half of 2027, with Medicus seeking to retain majority ownership.
- Value
- $135M
“We believe this proposed transaction will represent a meaningful step toward executing our strategic mandate to unlock the value of this important clinical-stage asset for our shareholders. The proposed transaction, in addition to establishing an independent public-market platform and access for Skinject, will also allow Medicus to participate in its future growth”
Dr. Raza Bokhari, Medicus Exec. Chairman and CEO